CERT vs. NARI, PGNY, MRUS, GDRX, BHC, MLTX, CLDX, MRVI, FTRE, and ACLX
Should you be buying Certara stock or one of its competitors? The main competitors of Certara include Inari Medical (NARI), Progyny (PGNY), Merus (MRUS), GoodRx (GDRX), Bausch Health Companies (BHC), MoonLake Immunotherapeutics (MLTX), Celldex Therapeutics (CLDX), Maravai LifeSciences (MRVI), Fortrea (FTRE), and Arcellx (ACLX). These companies are all part of the "medical" sector.
Certara (NASDAQ:CERT) and Inari Medical (NASDAQ:NARI) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.
Inari Medical has higher revenue and earnings than Certara. Inari Medical is trading at a lower price-to-earnings ratio than Certara, indicating that it is currently the more affordable of the two stocks.
74.0% of Certara shares are held by institutional investors. Comparatively, 91.0% of Inari Medical shares are held by institutional investors. 2.4% of Certara shares are held by insiders. Comparatively, 10.6% of Inari Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Inari Medical had 28 more articles in the media than Certara. MarketBeat recorded 30 mentions for Inari Medical and 2 mentions for Certara. Certara's average media sentiment score of 1.14 beat Inari Medical's score of 0.17 indicating that Certara is being referred to more favorably in the media.
Certara has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Comparatively, Inari Medical has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500.
Inari Medical has a net margin of -4.54% compared to Certara's net margin of -17.02%. Certara's return on equity of 4.08% beat Inari Medical's return on equity.
Inari Medical received 36 more outperform votes than Certara when rated by MarketBeat users. Likewise, 68.24% of users gave Inari Medical an outperform vote while only 34.92% of users gave Certara an outperform vote.
Certara presently has a consensus target price of $20.06, indicating a potential upside of 24.77%. Inari Medical has a consensus target price of $65.71, indicating a potential upside of 43.64%. Given Inari Medical's stronger consensus rating and higher possible upside, analysts clearly believe Inari Medical is more favorable than Certara.
Summary
Inari Medical beats Certara on 11 of the 18 factors compared between the two stocks.
Get Certara News Delivered to You Automatically
Sign up to receive the latest news and ratings for CERT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CERT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
